Effect of thalidomide and pentoxifylline on experimental autoimmune encephalomyelitis (EAE)

Experimental Neurology

Volumn 226, Issue 1, 2010, Pages 15-23

  Corrêa, José Otávio do Amaral ^a   Aarestrup, Beatriz Julião Vieira ^b   Aarestrup, Fernando Monteiro ^c  

^a FLUMINENSE FEDERAL UNIVERSITY   (Brazil)

^b University of Juiz de Fora   (Brazil)

^c FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

Author keywords

EAE; Multiple sclerosis; Nitric oxide; Pentoxifylline; Thalidomide; TNF alpha and Interferongamma

Indexed keywords

GAMMA INTERFERON; NITRIC OXIDE; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; IMMUNOSUPPRESSIVE AGENT; PHOSPHODIESTERASE INHIBITOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BRAIN TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG RESPONSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; SPINAL CORD; ANIMAL; BLOOD; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; GUINEA PIG; KINETICS; LEWIS RAT; NERVE FIBER; PATHOLOGY; RAT;

ANIMALS; BRAIN; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; GUINEA PIGS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-GAMMA; KINETICS; NERVE FIBERS; NITRIC OXIDE; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITORS; RATS; RATS, INBRED LEW; THALIDOMIDE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77957759989     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2010.04.007     Document Type: Article

References (33)

1. Aarestrup F.M., Gonçalves da Costa S.C., Sarno E.N. The effect of thalidomide on BCG-induced granulomas in mice. Bras. J. Med. Biol. Res. 1995, 28:1069-1076.
2. Alvord E.C., Shaw C.M., Hruby S. Approaches to the treatment of central nervous system autoimmune disease. Ann. Neurol. 1979, 6:469-473.
3. Balabanov R., Strand K., Kemper A., Lee J.Y., Popko B. Suppressor of cytokine signaling 1 expression protects oligodendrocytes from the deleterious effects of interferon-γ. J. Neurosci. 2006, 26(19):5143-5152.
4. Brenner T., Brocke S., Szafer F., Sobel R.A., Parkinson J.F., Perez D.H., Steinman L. Inhibition of nitric oxide synthase for treatment of experimental autoimmune encephalomyelitis. J. Immunol. 1997, 158(6):2940-2946.
5. Carvalho, M.C.A., 1999. Encefalomielite Autoimune Experimental. Importância da expressão de fibronectina no desenvolvimento das lesões. 132 p. Dissertação (Mestrado em Patologia Experimental) - Universidade Federal Fluminense.
6. Ching L.M., Browne W.L., Tchernegovski R., Gregory T., Baguley B.C., Palmer B.D. Interaction of thalidomide, thalidomide analogues of thalidomide and pentoxifylline with the anti-tumor agent 5, 6-dimethylxanthenone-4-acet acid: concomitant reduction of serum tumor necrosis factor-alpha and enhancement of anti-tumor activity. Brit. J. Can. 1998, 78(3):336-343.
7. Ding A., Nathan C.F., Stuer D.J. Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages: comparison of activating cytokines and evidence for independent production. J. Immunol. 1988, 141:2407-2503.
8. Fabis M.J., Scott G.S., Kean R.B., Koprowski H., Hooper D.C. Loss of blood-brain barrier integrity in the spinal cord is common to experimental allergic encephalomyelitis in knockout mouse models. Proc. Natl. Acad. Sci. 2007, 104(13):5656-5661.
9. Faria A.M., Weiner H.l. Oral tolerance: therapeutic implications for autoimmune diseases. Clin. Dev. Immunol. 2006, 13(2-4):143-157.
10. Furlan R., Villa P., Senaldi G., Martino G. TNFalpha in experimental diseases of the CNS. Meth. Mol. Med. 2004, 98:171-190.
11. Horga A., Horga J.F. Natalizumab em el tratamiento de la esclerosis múltiple. Rev. Neurol. 2007, 45(5):293-303.
12. Illes Z., Stern J.N., Keskin D.B., Reddy J., Brosnan C.F., Waldner H., et al. Copolymer effects on microglia and T cells in the central nervous system of humanized mice. Eur. J. Immunol. 2005, 35:3683-3693.
13. Issazadeh S., Ljungdahl A., Höjeberg B., Mustafa M., Olsson T. Cytokine production in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis: dynamics of mRNA expression for interleukin10, interleukin-12, cytolysin, tumor necrosis factor α and tumor necrosis factorβ. J. Neuroimmunol. 1995, 61:205-212.
14. h2) cells cause experimental allergic encephalomyelitis in immunodeficient hosts rather than protecting them from disease. J. Exp. Med. 1997, 186:307.
15. Lassmann, H., 2009. Axonal and neuronal pathology in multiple sclerosis: what have we learnt from animal models. Exp. Neu. Mon. Oct 19.
16. Lassmann H., Wisniewski H.M. Chronic relapsing experimental allergic encephalomyelitis: clinicopathological comparison with multiple sclerosis. Arch. Neurol. 1979, 36(490):1979.
17. Leadbetter E.A., Bourque C.R., Devaux B., Olson C.D., Sunshine G.H., Hirani S., et al. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide. J. Immunol. 1998, 161(1):504-512.
18. Macmicking J.D., Willenborg D.O., Weidemann M.J., Rockett K.A., Cowden W.B. Elevated secretion of reactive nitrogen and oxygen intermediates by inflammatory leukocytes in hyperacute experimental autoimmune encephalomyelitis: enhancement by the soluble products of encephalitogenic T cells. J. Exp. Med. 1992, 176(1):303-307.
19. Melanson M., Miao P., Eisenstat D., Gong Y., Gu X., Au K., Zhu W., Begum F., Frost E., Namaka M. Experimental autoimmune encephalomyelitis-induced upregulation of tumor necrosis factor-alpha in the dorsal root ganglia. Mult. Scler. Aug 10 2009, 3:22-35.
20. Mohamed A., Tarhuni H., Dufan T., Benghuzzi H., Tucci M. The use of digital technology to assess the severity of the experimental allergic encephalomyelitis (EAE) spinal cord lesion. Biomed. Sci. Instrum. 2004, 40:419-423.
21. Moreira M.A., Felipe E., Mendes M.F., Tilbery C.P. Multiple sclerosis: descriptive study of its clinical forms in 302 cases. Arq. Neuropsiquiatr. 2000, 58(2-B):460-466.
22. Noel P., Nelson S., Bokulic R., Bagby G., Lippton H., Lipscomb G., Summer W. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci. 1998, 47:1023-1029.
23. Ponomarev Ed., Maresz K., Tan Y., Dittel B.N. CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J. Neurosci. 2007, 3;27(40):10714-10721.
24. Pugliati M., Rosati G., Carton H., Riise T., Drulovic J., et al. The Epidemiology of multiple sclerosis in Europe. Eur. J. Neurol. 2006, 13:700-722.
25. Selmaj K.W., Raine C.S. Experimental autoimmune encephalomyelitis: immunotherapy with anti-tumor necrosis factor antibodies and soluble tumor necrosis factor receptors. Neurology 1995, 45(6 Suppl (6):S44-S49.
26. Seungjoon Kim, Changjong M., Myung B.W., Hyungmin K., Naoyuki T., Yoh M., Taekyun S. Enhanced expression of constitutive and inducible forms of nitric oxide synthase in autoimmune encephalomyelitis. J. Vet. Sci. 2000, 1(1):11-17.
27. Sommer N., Loschmann P.A., Northoff G.H., Wellwe M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1995, 1:244-248.
28. Stüve O., Youssef S., Weber M.S., Nessler S., Von Büdingen H.C., Hemmer B., et al. Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity. J. Clin. Invest. 2006, 116(4):1037-1044.
29. Teo S.K., Colburn W.A., Tracewell W.G., Kook K.A., Stirling D.I., Jaworsky M.S., et al. Clinical pharmacokinetics of thalidomide. Clin. Pharmacokinet. 2004, 43(5):311-327.
30. Tilbery C.P. Esclerose Múltipla no Brasil: Aspectos Clínicos e Terapêuticos 2005, Atheneu, São Paulo, 18-89.
31. Weber M.S., Zamvil S.S. Statins and demyelination. Curr. Top. Microbiol. Immunol. 2008, 318:313-324.
32. Weber M.S., Youssef S., Dunn S.E., Prod'homme T., Neuhaus O., Stuve O., Greenwood J., Steinman L., Zamvil S.S. Statins in the treatment of central nervous system autoimmune disease. J. Neuroimmunol. Sep. 2006, 178(1-2):140-148.
33. Yanying Z., Bingjie G., Xiaohui J., Xinsheng D., Chunjie S., Feichi W. Sinomenine, an antirheumatic alkaloid, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. Biol. Pharm. Bull. 2007, 30(8):1438-1444.